Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Myocardial fibrosis and calcification are attenuated by microRNA–129-5p targeting Asporin and Sox9 in cardiac fibroblasts
Lejla Medzikovic, Laila Aryan, Grégoire Ruffenach, Min Li, Nicoletta Savalli, Wasila Sun, Shervin Sarji, Jason Hong, Salil Sharma, Riccardo Olcese, Gregory Fishbein, Mansoureh Eghbali
Lejla Medzikovic, Laila Aryan, Grégoire Ruffenach, Min Li, Nicoletta Savalli, Wasila Sun, Shervin Sarji, Jason Hong, Salil Sharma, Riccardo Olcese, Gregory Fishbein, Mansoureh Eghbali
View: Text | PDF
Research Article Cardiology

Myocardial fibrosis and calcification are attenuated by microRNA–129-5p targeting Asporin and Sox9 in cardiac fibroblasts

  • Text
  • PDF
Abstract

Myocardial fibrosis and calcification associate with adverse outcomes in nonischemic heart failure. Cardiac fibroblasts (CF) transition into myofibroblasts (MF) and osteogenic fibroblasts (OF) to promote myocardial fibrosis and calcification. However, common upstream mechanisms regulating both CF-to-MF transition and CF-to-OF transition remain unknown. microRNAs are promising targets to modulate CF plasticity. Our bioinformatics revealed downregulation of miR–129-5p and upregulation of its targets small leucine–rich proteoglycan Asporin (ASPN) and transcription factor SOX9 as common in mouse and human heart failure (HF). We experimentally confirmed decreased miR–129-5p and enhanced SOX9 and ASPN expression in CF in human hearts with myocardial fibrosis and calcification. miR–129-5p repressed both CF-to-MF and CF-to-OF transition in primary CF, as did knockdown of SOX9 and ASPN. Sox9 and Aspn are direct targets of miR–129-5p that inhibit downstream β-catenin expression. Chronic Angiotensin II infusion downregulated miR–129-5p in CF in WT and TCF21-lineage CF reporter mice, and it was restored by miR–129-5p mimic. Importantly, miR–129-5p mimic not only attenuated progression of myocardial fibrosis, calcification marker expression, and SOX9 and ASPN expression in CF but also restored diastolic and systolic function. Together, we demonstrate miR–129-5p/ASPN and miR–129-5p/SOX9 as potentially novel dysregulated axes in CF-to-MF and CF-to-OF transition in myocardial fibrosis and calcification and the therapeutic relevance of miR–129-5p.

Authors

Lejla Medzikovic, Laila Aryan, Grégoire Ruffenach, Min Li, Nicoletta Savalli, Wasila Sun, Shervin Sarji, Jason Hong, Salil Sharma, Riccardo Olcese, Gregory Fishbein, Mansoureh Eghbali

×

Figure 5

SOX9 and ASPN promote both CF-to-MF and CF-to-OF transition.

Options: View larger image (or click on image) Download as PowerPoint
SOX9 and ASPN promote both CF-to-MF and CF-to-OF transition.
(A) AngII- ...
(A) AngII- and TGF-β–induced expression of Sox9 and Aspn transcripts in CF upon Sox9 or Aspn knockdown as assessed by qPCR. (B) SOX9 and ASPN protein expression in CF upon Sox9 or Aspn knockdown with representative Western blots. (C) AngII- and TGF-β–induced CF proliferation upon Sox9 or Aspn knockdown as assessed by CCK8 assay. (D) CF migration upon Sox9 or Aspn knockdown as assessed by scratch wound assay. (E) AngII- and TGF-β–induced CF collagen production upon Sox9 or Aspn knockdown as assessed by soluble Sirius red assay. (F) AngII- and TGF-β–induced αSMA expression in CF upon Sox9 or Aspn knockdown as assessed by immunofluorescence. Scale bar: 10 μm. (G) Osteogenic growth medium–induced calcium nodules (dark red, arrows) in CF upon Sox9 or Aspn knockdown as assessed by alizarin red staining. Scale bar: 20 μm. (H and I) AngII- and TGF-β–induced expression of Postn, Runx2, and Alp3 transcripts in CF upon Sox9 or Aspn knockdown as assessed by qPCR. (J) Expression of active β-catenin in CF upon Sox9 or Aspn knockdown as assessed by Western blot. Data presented as mean ± SEM; n = 3–4 independent experiments. Student’s t test (B) or ANOVA with Holm-Bonferroni post hoc correction. #P < 0.05 versus NC mimic ctrl stimulus, ##P < 0.01 versus NC mimic ctrl stimulus, ###P < 0.001 versus NC mimic ctrl; *P < 0.05, **P < 0.01, ***P < 0.001. AngII, Angiotensin II; NC, negative control.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts